INSIDE THIS ISSUE
-New Clinical and Billing Information
-New, Revised, and Deleted HCPCS® Codes Now Available
-New CPT® Codes Now Available
-Quarterly ASP (Average Sales Price) Pricing File Released
-January 2021 NOC (Not Otherwise Classified) Pricing File
-Hospital OPPS (Outpatient Prospective Payment System) Update
Large Price Changes:
We identify and report on the codes with the most substantial pricing increases or decreases each month and detail the rationale for the change.
Of the 112 AWP Drug Code Price changes this month, 29 (26%) were price decreases. The table in the Drug Reimbursement Code Price Updates section includes all AWP drug Code Price changes for this month. Please note: These numbers represent AWP Code Price changes only. See below for examples of codes with significant price changes this month.
LOOK UP PRICES NOW:
- J9395 Injection, fulvestrant, 25 mg, 5%
- J2405 Ondansetron hydrochloride, per 1 mg, 5%
- A4456 Adhesive remover, wipes, any type, each (Code Price is based on median pricing
- J9209 Injection, mesna, 200 mg, 61%
- S0109 Methadone, oral, 5 mg, 20%
- E0570 Nebulizer, with compressor (Code Price based on median pricing methodology), 42%
New, Revised, and Deleted HCPCS® Codes Now Available
CMS (Centers for Medicare & Medicaid Services) released their annual HCPCS® File for January 2021 which includes all New, Deleted, and Revised HCPCS® Codes. New codes have been added to www.ReimbursementCodes.com These codes became effective for Medicare billing for dates of service on and after January 1, 2021. Below is the list of new, deleted, and revised HCPCS® codes that RJ Health maintains in their database:
New HCPCS® Codes
A9591 Fluoroestradiol f 18, diagnostic, 1 millicurie
C1052 Hemostatic agent, gastrointestinal, topical
C9068 Copper cu-64, dotatate, diagnostic, 1 millicurie
C9069 Injection, belantamab mafodontin-blmf, 0.5 mg
C9070 Injection, tafasitamab-cxix, 2 mg
C9071 Injection, viltolarsen, 10 mg
C9072 Injection, immune globulin (asceniv), 500 mg
C9073 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
G0088 Professional services, initial visit, for the administration of anti-infective, pain management, chelation, pulmonary hypertension, inotropic, or other intravenous infusion drug or biological (excluding chemotherapy or other highly complex drug or biological) for each infusion drug administration calendar day in the individual’s home, each 15 minutes
G0089 Professional services, initial visit, for the administration of subcutaneous immunotherapy or other subcutaneous infusion drug or biological for each infusion drug administration calendar day in the individual’s home, each 15 minutes
G0090 Professional services, initial visit, for the administration of intravenous chemotherapy or other highly complex infusion drug or biological for each infusion drug administration calendar day in the individual’s home, each 15 minutes
J0693 Injection, cefiderocol, 5 mg
J1823 Injection, inebilizumab-cdon, 1 mg
J7212 Factor viia (antihemophilic factor, recombinant)-jncw (sevenfact), 1 microgram
J7352 Afamelanotide implant, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9223 Injection, lurbinectedin, 0.1 mg
J9281 Mitomycin pyelocalyceal instillation, 1 mg
J9316 Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg
J9317 Injection, sacituzumab govitecan-hziy, 2.5 mg
M0239 Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring
M0243 Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring
Q0239 Injection, bamlanivimab-xxxx, 700 mg
Q0243 Injection, casirivimab and imdevimab, 2400 mg
Q5122 Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg
S0013 Esketamine, nasal spray, 1 mg
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2
Deleted HCPCS® Codes
C9060 Fluoroestradiol f18, diagnostic, 1 mci
C9062 Injection, daratumumab 10 mg and hyaluronidase-fihj
C9064 Mitomycin pyelocalyceal instillation, 1 mg
C9066 Injection, sacituzumab govitecan-hziy, 2.5 mg
C9745 Nasal endoscopy, surgical; balloon dilation of eustachian tube
C9747 Ablation of prostate, transrectal, high intensity focused ultrasound (hifu), including imaging guidance
C9749 Repair of nasal vestibular lateral wall stenosis with implant(s)
Revised HCPCS® Codes
Previous Description: Factor VIIa (antihemophilic factor, recombinant), per 1 microgram
Revised Description: Factor viia (antihemophilic factor, recombinant), (novoseven rt), 1 microgram
New CPT® Codes Now Available
The American Medical Association (AMA) released two new CPT® codes effective for billing on or after January 1, 2021. Both codes have been added to www.ReimbursementCodes.com and are listed below:
90377 Rabies immune globulin, heat- and solvent/detergent-treated (RIg-HT S/D), human, for intramuscular and/or subcutaneous use (Code Price is per 150 IU) (Uses median pricing methodology)
90697 Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use
Quarterly ASP (Average Sales Price) File Released:
Another quarter has passed, and this means CMS has released the January 2021 ASP pricing and revisions files. These rates are effective January 1, 2021 through March 31, 2021. This new ASP pricing file is incorporated in our own data and website. To view the most recent revised rates simply click on the Medicare Allowable tab on the pricing screen. Please note: Code(s) with revisions are noted in parenthesis.
January 2020 ASP Pricing File (Codes: J7682)
April 2020 ASP Pricing File (Codes: J7682)
October 2020 ASP Pricing File (Codes: J0642, J9055, J9305, Q4133)
As per CMS, “the payment amounts in the quarterly ASP files are 106 percent of the Average Sales Price (ASP) calculated from data submitted by drug manufacturers. The quarter to quarter price changes are generally the result of updated data from the manufacturers of these drugs.”
Our data files and website have incorporated these changes. As a reminder, we display the most recent revised rate on the Medicare Allowable tab on the pricing screen. To view previous Medicare Allowable rates for a quarter (if revised), click on the appropriate Effective Date on the same screen. Please Note: ASP rate revisions are retroactive to the beginning of the quarter.
January 2021 NOC (Not Otherwise Classified) Pricing File
CMS released the January 1, 2021 NOC Pricing file.
To view the NOC pricing file on the website, search on a NOC (Not Otherwise Classified) code, product or NDC and click on the link “Listing of CMS ASP+6% rates for NOCs” under Additional Information on the left side of the screen.
Hospital OPPS (Outpatient Prospective Payment System) Update:
If billing under the Hospital OPPS (Outpatient Prospective Payment System) the January 1, 2021 – March 31, 2021 APC rates are now available on the Pricing tab under APC. The APC tab will also provide you with the APC and Status Indicator (SI), if established.
Each month the RJ Health Clinical Committee meets to review newly approved drugs, dosing, ICD-10 assignments, coding assignments and billable units. Additionally, we discuss questions and concerns our customers raise to ensure we are providing the most accurate and current information in our data and on our website.
Drug Reimbursement Code Price Updates:
This month, during our review of the 3079 Reimbursement HCPCS/CPT® Codes in our system, we identified 112 Drug Codes that required a recalculation of their AWP Code Price. Log in to www.ReimbursementCodes.com to view the pricing updates for these codes.
86580 A4259 J0153 J1000 J1720 J2700 J7314 J9201 Q4213 S0157 90376 A4371 J0171 J1020 J1940 J2770 J7345 J9209 Q4231 S0164 90619 A4394 J0256 J1071 J2020 J2787 J7503 J9211 Q4232 S0171 90691 A4456 J0280 J1170 J2150 J2800 J7504 J9266 S0017 S0187 90698 A6248 J0295 J1250 J2260 J3245 J7507 J9268 S0020 90702 A9513 J0348 J1335 J2274 J3315 J8515 J9370 S0028 90713 A9588 J0461 J1364 J2278 J3430 J8540 J9395 S0030 90715 B4103 J0583 J1450 J2300 J3465 J9036 Q0161 S0032 90734 C9113 J0595 J1455 J2405 J7030 J9040 Q0162 S0077 A4245 C9122 J0604 J1572 J2510 J7100 J9118 Q0163 S0093 A4250 E0570 J0670 J1580 J2540 J7175 J9171 Q0169 S0109 A4256 J0131 J0713 J1645 J2690 J7189 J9178 Q4180 S0119
LOOK UP PRICES NOW:
Drugs/Devices: New/Updated Billing & Clinical Information
As new drugs come to market we review them for possible inclusion in our database. When a new drug is added to the database, we develop detailed clinical and billing information for the drug if appropriate.
During the past month, our review identified one new drugs which needed to be added to our database and zero drugs that required updating.
DANYELZA® (naxitamab-gqgk) injection, for intravenous use-By Y-mAbs Therapeutics, Inc (NOC Codes: J9999, C9399)
Check back next month for updates.
Our tools and data:
© 2019 RJ Health Systems International, LLC. All rights reserved. This newsletter and its contents are copyright protected. No part of this newsletter may be reproduced in any manner by any means without written permission of RJ Health Systems International, LLC.
CPT copyright 2019 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.